

**STERLING BIOTECH LIMITED**

Regd. Office: 43, Atlanta Building, Nariman Point, Mumbai - 400 021

**UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2013**

**PART I**

(Rs. in Lacs)

Sr. No.	Particulars	Three Months ended			Nine Months ended		Twelve Months ended
		30/09/2013	30/06/2013	30/09/2012	30/09/2013	30/09/2012	31/12/2012
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	<b>Income from Operations</b>						
a)	Net Sales/Income from Operations	16,134.99	20,021.33	19,802.42	56,732.09	63,122.59	83,477.42
b)	Other Operating Income	111.36	121.46	203.21	373.07	645.56	702.31
c)	<b>Total Income from Operations</b>	<b>16,246.35</b>	<b>20,142.79</b>	<b>20,005.63</b>	<b>57,105.16</b>	<b>63,768.15</b>	<b>84,179.73</b>
2	<b>Expenses</b>						
a)	Cost of materials consumed	8,049.25	15,280.20	12,086.87	39,091.94	42,234.94	61,445.02
b)	Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	2,954.81	(664.73)	412.42	1,856.54	1,730.88	(3,350.82)
d)	Employee benefits expense	1,334.53	1,403.81	1,339.62	4,100.31	4,040.20	5,368.03
e)	Depreciation and amortization expense	6,334.62	6,319.28	6,535.65	18,988.04	19,219.25	26,004.96
f)	Other Expenses	1,185.64	1,898.33	1,352.21	4,450.15	3,906.65	5,255.12
g)	<b>Total Expenses</b>	<b>19,858.85</b>	<b>24,236.89</b>	<b>21,726.77</b>	<b>68,486.98</b>	<b>71,131.92</b>	<b>94,722.31</b>
3	<b>Profit / (Loss) from Operations before Other Income and finance Costs (1-2)</b>	<b>(3,612.50)</b>	<b>(4,094.10)</b>	<b>(1,721.14)</b>	<b>(11,381.82)</b>	<b>(7,363.77)</b>	<b>(10,542.58)</b>
4	Other Income	0.00	0.00	0.00	0.00	0.00	0.00
5	<b>Profit / (Loss) from Ordinary activities before finance costs (3+4)</b>	<b>(3,612.50)</b>	<b>(4,094.10)</b>	<b>(1,721.14)</b>	<b>(11,381.82)</b>	<b>(7,363.77)</b>	<b>(10,542.58)</b>
6	Finance Costs	11,098.48	10,587.73	9,629.04	32,237.40	30,932.94	41,232.82
7	<b>Profit / (Loss) from Ordinary Activities after finance costs but before tax (5-6)</b>	<b>(14,710.98)</b>	<b>(14,681.83)</b>	<b>(11,350.18)</b>	<b>(43,619.22)</b>	<b>(38,296.71)</b>	<b>(51,775.40)</b>
8	Tax expense						
a)	Current	0.00	0.00	0.00	0.00	0.00	0.00
b)	Deferred	(4,773.00)	(4,764.00)	(3,683.00)	(14,153.00)	(12,425.00)	(16,798.00)
c)	Total	(4,773.00)	(4,764.00)	(3,683.00)	(14,153.00)	(12,425.00)	(16,798.00)
9	<b>Net Profit / (Loss) from Ordinary Activities after tax (7-8)</b>	<b>(9,937.98)</b>	<b>(9,917.83)</b>	<b>(7,667.18)</b>	<b>(29,466.22)</b>	<b>(25,871.71)</b>	<b>(34,977.40)</b>
10	Extraordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
11	<b>Net Profit / (Loss) for the period (9+10)</b>	<b>(9,937.98)</b>	<b>(9,917.83)</b>	<b>(7,667.18)</b>	<b>(29,466.22)</b>	<b>(25,871.71)</b>	<b>(34,977.40)</b>
12	Prior year adjustment	0.00	0.00	0.00	0.00	0.00	0.00
13	<b>Profit available for appropriation</b>	<b>(9,937.98)</b>	<b>(9,917.83)</b>	<b>(7,667.18)</b>	<b>(29,466.22)</b>	<b>(25,871.71)</b>	<b>(34,977.40)</b>
14	Paid-up equity share capital (Face Value of Re.1/- per share)	2,678.74	2,678.74	2,678.74	2,678.74	2,678.74	2,678.74
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year						184,399.00
16.i	Earnings Per Share (EPS) (before extraordinary items) (F.V. of Re.1/- each) (not annualised)						
a)	Basic	(3.71)	(3.70)	(2.86)	(11.00)	(9.66)	(13.06)
b)	Diluted	(3.29)	(3.28)	(2.53)	(9.74)	(8.55)	(11.56)
16.ii	Earnings Per Share (EPS) (after extraordinary items) (F.V. of Re.1/- each) (not annualised)						
a)	Basic	(3.71)	(3.70)	(2.86)	(11.00)	(9.66)	(13.06)
b)	Diluted	(3.29)	(3.28)	(2.53)	(9.74)	(8.55)	(11.56)

**STERLING BIOTECH LIMITED**  
 Regd. Office: 43, Atlanta Building, Nariman Point, Mumbai - 400 021

Select Information for the Quarter ended 30 September 2013

**PART II**

Sr. No.	Particulars	Three Months ended			Nine Months ended		Twelve Months ended
		30/09/2013	30/06/2013	30/09/2012	30/09/2013	30/09/2012	31/12/2012
<b>A</b>	<b>PARTICULARS OF SHAREHOLDING</b>						
1	Public Shareholding						
	- Number of shares	131,861,090	131,861,090	131,861,090	131,861,090	131,861,090	131,861,090
	- Percentage of shareholding	49.23%	49.23%	49.23%	49.23%	49.23%	49.23%
2	Promoters and Promoter Group Shareholding						
	a) Pledged/Encumbered						
	Number of shares	50,816,835	50,816,835	50,816,835	50,816,835	50,816,835	50,816,835
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	55.94%	55.94%	55.94%	55.94%	55.94%	55.94%
	Percentage of shares (as a % of the total share capital of the Company)	18.97%	18.97%	18.97%	18.97%	18.97%	18.97%
	b) Non-encumbered						
	Number of shares	40,023,300	40,023,300	40,023,300	40,023,300	40,023,300	40,023,300
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	44.06%	44.06%	44.06%	44.06%	44.06%	44.06%
	Percentage of shares (as a % of the total share capital of the Company)	14.94%	14.94%	14.94%	14.94%	14.94%	14.94%

Sr. No.	Particulars	Quarter ended 30/09/2013
<b>B</b>	<b>INVESTOR COMPLAINTS</b>	
	Pending at the beginning of the Quarter	0
	Received during the quarter	8
	Disposed of during the quarter	8
	Remaining unresolved at the end of the quarter	0

**Notes:**

- 1 The company's operations fall under single segment hence segment reporting as defined in Accounting Standard 17 is not applicable.
- 2 The above Financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors in its meeting held on 13 November 2013.
- 3 The Statutory Auditors have carried out a limited review of the financial results for the quarter ended 30 September 2013
- 4 The Company has Overseas Subsidiaries and there are no business operations in the subsidiary companies.
- 5 Previous period figures have been regrouped/reclassified, wherever necessary.

**For and on Behalf of  
STERLING BIOTECH LIMITED**

Place : Mumbai  
Date : 13 November 2013.

**Chetan J. Sandesara  
Joint Managing Director**